Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆
Y. Di Filippo(Inserm), Henri Montaudié(Hôpital l'Archet), Bastien Oriano(Hôtel-Dieu de Paris), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), O. Dereure(Beth Israel Deaconess Medical Center), J.-P. Arnnault(Centre Hospitalier Universitaire Amiens-Picardie), Wendy Lefevre(Inserm), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), A. Dupuy(Université de Rennes), F. Brunet‐Possenti(Inserm), E. Maubec(Inserm), F. Aubin(Centre Hospitalier Universitaire de Besançon), Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jean‐Jacques Grob(Aix-Marseille Université), Clara Allayous(Inserm), Stéphane Dalle(Hospices Civils de Lyon), Laurent Mortier, P Stoebner, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), A Stephan(Laboratoire de Physique Corpusculaire de Caen), M. Beylot‐Barry(Université de Bordeaux)
Cited by 30
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k